Ahn H, Lee SY, Jung WJ, Pi J, Lee KH. Psoriasis treatment using minimally manipulated umbilical cord-derived mesenchymal stem cells: A case report. World J Clin Cases 2021; 9(23): 6798-6803 [PMID: 34447827 DOI: 10.12998/wjcc.v9.i23.6798]
Corresponding Author of This Article
Kye-Ho Lee, PhD, Stem Cell Rearch, STRI, 72 UNvillage-gil Yongsan-gu, Seoul 04420, South Korea. sylee@stc365.com
Research Domain of This Article
Dermatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 16, 2021; 9(23): 6798-6803 Published online Aug 16, 2021. doi: 10.12998/wjcc.v9.i23.6798
Psoriasis treatment using minimally manipulated umbilical cord-derived mesenchymal stem cells: A case report
Hyunjun Ahn, Sang Yeon Lee, Won-Ju Jung, Jia Pi, Kye-Ho Lee
Hyunjun Ahn, Sang Yeon Lee, Jia Pi, Kye-Ho Lee, bio Beauty&Health Company (bBHC)-Stem Cell Treatment and Research Institute (STRI), Seoul 04420, South Korea
Hyunjun Ahn, Department of Functional Genomics, University of Science and Technology KRIBB School, Deajeon 34113, South Korea
Won-Ju Jung, Stem Cell Treatment, 97.7 B&H Clinic, Seoul 04420, South Korea
Author contributions: Ahn H, Lee SY, Jung WJ and Lee KH designed the reports; Ahn H, Pi J and Jung WJ collected the patient’s clinical data; Ahn H, Pi J and Jung WJ analyzed the data; Ahn H and Pi J wrote the manuscript; Lee KH provided professional advice and revised the manuscript; all authors issued final approval for the version to be submitted.
Informed consent statement: The patient involved in this study gave his written informed consent authorizing disclosure of his protected health information.
Conflict-of-interest statement: All authors have no conflicts of interest to declare.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kye-Ho Lee, PhD, Stem Cell Rearch, STRI, 72 UNvillage-gil Yongsan-gu, Seoul 04420, South Korea. sylee@stc365.com
Received: January 13, 2021 Peer-review started: January 13, 2021 First decision: May 11, 2021 Revised: May 24, 2021 Accepted: July 6, 2021 Article in press: July 6, 2021 Published online: August 16, 2021 Processing time: 204 Days and 4.3 Hours
Abstract
BACKGROUND
Psoriasis is a chronic autoimmune disease that usually manifests as a red scaly epidermis, induration, and hyperproliferation of basal keratinocytes. About 2% of the world’s population suffers from psoriasis but there are no clear therapeutics yet. Recently, mesenchymal stem cells (MSCs) have been regarded as a therapeutic alternative for autoimmune diseases, as they possess immunosuppressive effects without risks. Human umbilical cord-derived MSCs effectively regulate immune cells and are characterized by low immunogenicity, which has many advantages in treating immune diseases.
CASE SUMMARY
The patient was a 47-year-old male, diagnosed with psoriasis in 1995. He had received various treatments for 25 years, but the psoriatic condition was not significantly improved. He was given three rounds of minimally manipulated umbilical cord-derived MSCs over 2 wk. The erythema gradually disappeared. Three months after the 1st round, all erythema completely disappeared, and the psoriasis did not recur.
CONCLUSION
Minimally manipulated umbilical cord-derived MSC transplantation can potentially treat patients who suffer from psoriasis.
Core Tip: In recent decades, interest in biomedical applications of mesenchymal stem cells (MSCs) has increased due to their anti-inflammatory, immunosuppressive, and immunomodulatory abilities. MSCs have been used to study a variety of human diseases without side effects. The human umbilical cord is an excellent source of MSCs. We sought to improve a patient’s psoriatic condition by using minimally manipulated umbilical cord-derived MSCs. In this case study, we report the efficacy of the minimally manipulated umbilical cord-derived MSC therapy to treat a patient with psoriasis.
